ORIGINAL ARTICLE Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 Harmony R. Reynolds, Samrachana Adhikari, Claudia Pulgarin, et al N Engl J Med May 1, 2020DOI: 10.1056/NEJMoa2008975 Abstract BACKGROUND There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiot...

ORIGINAL ARTICLE Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 Giuseppe Mancia, Federico Rea, Monica Ludergnani, et al N Engl J Med May 1, 2020DOI: 10.1056/NEJMoa2006923 Abstract BACKGROUND A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied. METHODS We carried out a po...

ORIGINAL ARTICLE Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Mandeep R. Mehra, Sapan S. Desai, SreyRam Kuy, et al N Engl J Med May 1, 2020DOI: 10.1056/NEJMoa2007621 Abstract BACKGROUND Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs...

Original Investigation April 6, 2020 Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Giacomo Grasselli, Alberto Zangrillo, Alberto Zanella, et al JAMA. Published online April 6, 2020. doi:10.1001/jama.2020.5394 Abstract Importance In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) emerged in China and has spread ...

Perspective Critical Supply Shortages — The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic Megan L. Ranney, Valerie Griffeth, Ashish K. Jha N Engl J Med 2020; 382:e41DOI: 10.1056/NEJMp2006141 On March 11, 2020, the World Health Organization designated “coronavirus disease 2019” (Covid-19) a global pandemic. As the number of cases in the United States continues to grow, political leaders are encouraging physical (or “social”...

Research Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal Laure Wynants, Ben Van Calster, Marc M J Bonten, et al BMJ 2020; 369:m1328 doi: https://doi.org/10.1136/bmj.m1328 Abstract Objective To review and critically appraise published and preprint reports of prediction models for diagnosing coronavirus disease 2019 (covid-19) in patients with suspected infection, for prognosis of patients with ...

ARTICLES|ONLINE FIRST Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Yeming Wang, Dingyu Zhang, Guanhua Du, et al Lancet Published:April 29, 2020 DOI:https://doi.org/10.1016/S0140-6736(20)31022-9 Summary Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, ...

Research Letter February 14, 2020 Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China Min Wei, Jingping Yuan, Yu Liu, et al JAMA. 2020;323(13):1313-1314. doi:10.1001/jama.2020.2131 Since December 8, 2019, an epidemic of coronavirus disease 2019 (COVID-19) has spread rapidly.1 As of February 6, 2020, China reported 31 211 confirmed cases of COVID-19 and 637 fatalities. Previous studies suggest that COVID-19 is more like...

COVID-19: From Hydroxychloroquine to Plasma Administration A number of colleagues and friends from outside the hospital have asked me whether they should take hydroxychloroquine for their COVID-19. A friend asked me whether he should take lopinavir-ritonavir even though he is not HIV-positive. A hospitalised patient requested administration of remdesivir regardless of the cost involved, and another patient even requested transfer to another hospital to receive the toci...

ORIGINAL ARTICLE FREE PREVIEW Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012–2017 John A. Jernigan, Kelly M. Hatfield, Hannah Wolford, et al N Engl J Med 2020; 382:1309-1319DOI: 10.1056/NEJMoa1914433 Abstract BACKGROUND Multidrug-resistant (MDR) bacteria that are commonly associated with health care cause a substantial health burden. Updated national estimates for this group of pathogens are needed to inform public health ac...